Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Weetabix Cereal Sold to Post in £1.4 Billion Deal



The cereal was sold by Shanghai-based Bright Food, which acquired a controlling stake in the company in 2012. Photo by freeimages.com/Adam Davis

Share this!

April 20, 2017 | by Sarah Hand, M.Sc.

US cereal brand Post Holdings has purchased the UK’s iconic Weetabix band in a deal worth £1.4 billion. The cereal was sold by Shanghai-based Bright Food, which acquired a controlling stake in the company in 2012.

Post is currently the third-largest cereal company in the US, specializing in other breakfast cereals including Honey Bunches of Oats and Grape-Nuts. Along it the popular breakfast cereal, the Weetabix portfolio includes Alpen muesli, Ready Brek, Barbara’s and Weetos.

Bright Food originally acquired Weetabix in the hopes that its popularity in China would grow over traditional Asian breakfast items. However, sales of Weetabix were insufficient to capture enough of the market share.

While sales of Weetabix remain highest in the UK, the breakfast cereal is exported to over 90 countries around the world. It is also primarily manufactured in the UK, with all of the wheat used in the product supplied by local farmers.

“We have long admired Weetabix as a leader in cereal and believe it will be a fantastic strategic fit within Post,” said Rob Vitale, Post’s President and CEO. “Combining together two category leaders continues our strategy of strengthening our portfolio in stable categories and diversifying into new markets, bringing much-loved brands to significantly more customers globally. We are excited about the growth opportunities that this acquisition brings.”

Weetabix employs around 1,800 people around the world, and CEO of the company Giles Turrell has already said that he doesn’t not expect there to be job cuts as a result of the transaction. “Post has no footprint or manufacturing in the UK,” said Turrell. “As long as we remain successful in the marketplace we will continue to manufacture at our plants here in Northamptonshire.”

Post’s annual revenues total $5 billion per year, with Weetabix bringing in £410 million in 2016. The deal is expected to be completed in the third quarter of 2017.

Keywords:  Food Industry, Food Manufacturing, Food Sales


Share this with your colleagues!

Samsung Bioepis and Takeda to Co-Develop Novel Biologic Drugs

August 22, 2017 - Biosimilars drugmaker Samsung Bioepis has joined forces with Takeda Pharmaceutical to develop biologic therapies in novel disease areas.

Featured In: Biotech News

Improving Administration of Blood Thinner Drugs through an Online Course for Nurses

August 22, 2017 - Patients’ refusal of blood thinners can influence a nurse’s decision to administer the drugs, but an online educational program could help to address this issue.

Featured In: Life Science News

Exploring the FDA’s Accelerated Approval Pathway

August 21, 2017 - Investigational new drugs that could fill an unmet medical need are sometimes granted “Accelerated Approval” by the US Food and Drug Administration (FDA) in an effort to make these medicines available to the patients who need them.

Featured In: Pharmaceutical News


One Patient’s Perspective on Clinical Trials


Planning and Conducting Trials of the Latest Immunotherapies

ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation

Medical Devices: Reviewing Regulatory Changes in the US and EU

Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.